Janssen Submits Supplemental New Drug Application to FDA for SPRAVATO CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults With Major Depressive Disorder Who Have Active Suicidal Ideation With Intent
October 03, 2019
October 03, 2019
TITUSVILLE, New Jersey, Oct. 3 -- Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:
* * *
- If approved, SPRAVATO(R) would be the first treatment for this severely ill population1 who historically have been excluded from antidepressant clinical trials
- Submission is based on data from the ASPIRE I & II trials evaluating the efficacy and safety of SPRAVATO(R) in adults with major depressive disorde . . .
* * *
- If approved, SPRAVATO(R) would be the first treatment for this severely ill population1 who historically have been excluded from antidepressant clinical trials
- Submission is based on data from the ASPIRE I & II trials evaluating the efficacy and safety of SPRAVATO(R) in adults with major depressive disorde . . .